INVESTIGATION OF SOLID DISPERSION APPROACH FOR THE IMPROVEMENT OF PHARMACEUTICAL CHARACTERISTICS OF TELMISARTAN USING A CENTRAL COMPOSITE DESIGN

RITU KAUSHIK; RAVINDER VERMA; VIKAS BUDHWAR; DEEPAK KAUSHIK

doi:10.22159/ijap.2023v15i5.47968

Authors

RITU KAUSHIK Department of Pharmaceutical Sciences, Maharishi Dayanand University, Rohtak-124001, India https://orcid.org/0000-0001-7481-1605
RAVINDER VERMA Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani-127021, India https://orcid.org/0000-0003-3397-703X
VIKAS BUDHWAR Department of Pharmaceutical Sciences, Maharishi Dayanand University, Rohtak-124001, India
DEEPAK KAUSHIK Department of Pharmaceutical Sciences, Maharishi Dayanand University, Rohtak-124001, India https://orcid.org/0000-0002-3286-196X

DOI:

https://doi.org/10.22159/ijap.2023v15i5.47968

Keywords:

Telmisartan, Polyvinyl pyrrolidine K25, Polyethylene glycol 4000, Solid dispersion, Solvent evaporation, Central composite design

Abstract

Objective: The goal of this study was to use a solid dispersion approach to improve the aqueous solubility and dissolution rate of Telmisartan.

Methods: Design of experiment trials was conducted following a central composite design with different combinations of polymers and stirrer rpm and the selected responses (drug release, entrapment efficiency) were determined. The selected optimized formulation was characterized by Fourier-transform infrared spectroscopy, differential scanning calorimetry, scanning electron microscopy, and X-ray diffraction, which reflected the changes that occurred in API and excipients after conversion in to the formulation.

Results: In the design of experiments, central composite design was implemented and it was observed that polymers concentration (polyvinyl pyrrolidine K25, polyethylene glycol 4000) and stirrer rpm were having a significant impact on the responses (drug release, entrapment efficiency), and variables were having p-value<0.05 which reflected the significant impact. The results of stability study showed a significant no decrease in drug assay values, which reflected the stability behavior of the formulation. The results of comparative dissolution studies revealed that the optimized formulation have improved the drug solubility and dissolution rate.

Conclusion: It can be concluded that optimized telmisartan-loaded solid dispersion improved the solubility and dissolution rate of Telmisartan. The optimized formulation was having release>85% release within 30 min. Further, the stability of the formulation was also assessed under the accelerated condition as per ICH which reflected their stability. So, this approach can be employed for improving dissolution rate of other BCS II class drugs.

Downloads

Download data is not yet available.

References

Sharma KS, Sahoo J, Agrawal S, Kumari A. Solid dispersions: a technology for improving bioavailability. JAPLR 2019;8(4):127-33. doi: 10.15406/japlr.2019.08.00326.

Sugawara M, Singh N. The use of an in vitro dissolution and assimilation system to evaluate oral assimilation of two weak bases in pH-independent controlled-discharge formulations. Eur J Pharm Sci. 2011;26:1-8. doi: 10.1016/j.ejps.02.017.

Vemula VR, Lagishetty V, Lingala S. Solubility enhancement approaches. Int J Pharm Sci Rev Res Dev. 2010;5(1):41-51.

Arora SC, Sharma PK. Development, characterization and solubility study of SD of cefixime trihydrate by solvent evaporation method. Int J Drug Dev Res. 2010;2:424-30.

Chiou WL, Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J Pharm Sci. 1969;58(12):1505-10. doi: 10.1002/jps.2600581218. PMID 5353269.

Kaushik R, Budhwar V, Kaushik D. An overview on recent patents and technologies on solid dispersion. Recent Pat Drug Deliv Formul. 2020;14(1):63-74. doi: 10.2174/1872211314666200117094406, PMID 31951172.

Sarangi MK, Singh N. Solid dispersion-a novel approach for enhancement of bioavailability of poorly soluble drug in oral drug delivery system. Glob J Pharmaceutical Sci. 2017;3(2):22-33.

Shaikh A, Bhide P, Nachinolkar R. Solubility enhancement of celecoxib by solid dispersion technique and incorporation into topical gel. Asian J Pharm Clin Res. 2019;12(2):294-300. doi: 10.22159/ajpcr.2019.v12i2.29784.

Sehgal N, Gupta NV, Dv G, PS. Fabrication and evaluation of solid dispersion containing glibenclamide. Asian J Pharm Clin Res. 2018;11(8):158-61. doi: 10.22159/ajpcr.2018.v11i8.26236.

Kumar A, Sahoo SK, Padhee K. Review on solubility enhancement approaches for hydrophobic drugs. Int J Comp Pharm. 2011;3:1-7.

Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60. doi: 10.1016/S0939-6411(00)00076-X, PMID 10840192.

Leuner C, Dressman J. Improving drug solubility for oral delivery using SDs. Eur J Pharm Biopharm. 2001;50:45-50.

Verma R, Kaushik D. Development, optimization, characterization and impact of in vitro lipolysis on drug release of telmisartan loaded SMEDDS. Drug Deliv Lett. 2019;9(4):330-40. doi: 10.2174/2210303109666190614120556.

Cao Y, Shi LL, Cao QR, Yang M, Cui JH. In vitro characterization and oral bioavailability of organic solvent-free solid dispersions containing telmisartan. Iran J Pharm Res. 2016;15(2):385-94. PMID 27642309.

Borbas E, Nagy ZK, Nagy B, Balogh A, Farkas B, Tsinman O. The effect of formulation additives on in vitro dissolution-absorption profile and in vivo bioavailability of telmisartan from brand and generic formulations. Eur J Pharm Sci. 2018;114:310-7. doi: 10.1016/j.ejps.2017.12.029, PMID 29305981.

Tran PHL, Tran HTT, Lee BJ. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release. 2008;129(1):59-65. doi: 10.1016/j.jconrel.2008.04.001, PMID 18501462.

Chandra A, Ghate MV, Aithal KS, Lewis SA. In silico prediction coupled with in vitro experiments and absorption modeling to study the inclusion complex of telmisartan with modified beta-cyclodextrin. J Incl Phenom Macrocycl Chem. 2018;91(1-2):47-60. doi: 10.1007/s10847-018-0797-x.

Zhong L, Zhu X, Luo X, Su W. Dissolution properties and physical characterization of telmisartan−chitosan solid dispersions prepared by mechanochemical activation. AAPS PharmSciTech. 2013;14(2):541-50. doi: 10.1208/s12249-013-9937-1.

Pandey P, Chellappan DK, Tambuwala MM, Bakshi HA, Dua K, Dureja H. Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system. Int J Biol Macromol. 2019;141:596-610. doi: 10.1016/j.ijbiomac.2019.09.023. PMID 31494160.

Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60. doi: 10.1016/s0939-6411(00)00076-x, PMID 10840192.

Mannem V, Suryadevara V, Doppalapudi S. Formulation and evaluation of telmisartan solid dispersions using Entada scandens seed starch and poloxamer-188 as superdisintegrants. Asian J Pharm Clin Res. 2018;11(9):474-81. doi: 10.22159/ajpcr.2018.v11i9.28422.

Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131-44. doi: 10.1016/s0378-5173(01)00891-2, PMID 11755266.

Chauhan H, Hui-Gu C, Atef E. Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci. 2013;102(6):1924-35. doi: 10.1002/jps.23539, PMID 23580406.

Smikalla MM, Urbanetz NA. The influence of povidone K17 on the storage stability of solid dispersions of nimodipine and polyethylene glycol. Eur J Pharm Biopharm. 2007;66(1):106-12. doi: 10.1016/j.ejpb.2006.08.018, PMID 17055711.

Pignatello R, Ferro M, Puglisi G. Preparation of solid dispersions of nonsteroidal anti-inflammatory drugs with acrylic polymers and studies on mechanisms of drug-polymer interactions. AAPS PharmSciTech. 2002;3(2):E10. doi: 10.1208/pt030210. PMID 12916947.

Mahmood HSh, Almusawi JM, Alaayedi MH, Obaiss MK, Mahdi Sura S, Abdulmahdi Ml. Formulation and evaluation of flurbiprofen solid dispersion formulation and evaluation of flurbiprofen solid dispersion. Ijppr Hum. 2016;7(3):78-90.

Verma R, Mittal V, Kaushik D. Self-micro emulsifying drug delivery system: a vital approach for bioavailability enhancement. Int J ChemTech Res. 2017;10(7):515-28.

Sekiguchi K, Obi N. Studies on absorption of the eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull. 1961;9(11):866-72. doi: 10.1248/cpb.9.866.

Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-302. doi: 10.1002/jps.2600600902, PMID 4935981.

Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. International Journal of Pharmaceutics. 2002;231(2):131-44. doi: 10.1016/S0378-5173(01)00891-2.

Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K. Improved dissolution of ofloxacin via SD. Int J Pharm. 1997;156:175-80. doi: 10.1016/S.0378-5173(97)00196-8

Majerik V, Charbit G, Badens E, Horvath G, Szokonya L, Bosc N. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. J Supercrit Fluids. 2007;40(1):101-10. doi: 10.1016/j.supflu.2006.03.027.

Verma R, Kaushik A, Almeer R, Rahman MH, Abdel-Daim MM, Kaushik D. Improved pharmacodynamic potential of rosuvastatin by self-nano emulsifying drug delivery system: an in vitro and in vivo evaluation. Int J Nanomedicine. 2021;16:905-24. doi: 10.2147/IJN.S287665, PMID 33603359.

Cutler L, Howes C, Deeks NJ, Buck TL, Jeffrey P. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J Pharm Sci. 2006;95(9):1944-53. doi: 10.1002/jps.20658, PMID 16850390.

Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058-66. doi: 10.1021/js980403l. PMID 10514356.

Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-87. doi: 10.1016/j.ejps.2006.04.016, PMID 16815001.

Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug-polymer solid dispersions. Int J Pharm. 2006;308(1-2):69-83. doi: 10.1016/j.ijpharm.2005.10.026, PMID 16324806.

Johari GP, Kim S, Shanker RM. Dielectric studies of molecular motions in amorphous solid and ultraviscous acetaminophen. J Pharm Sci. 2005;94(10):2207-23. doi: 10.1002/jps.20455, PMID 16136559.

Wang X, Michoel A, Van den Mooter G. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int J Pharm. 2005;303(1-2):54-61. doi: 10.1016/j.ijpharm.2005.07.002. PMID 16105723.

Al-Japairai KAS, Alkhalidi HM, Mahmood S, Almurisi SH, Doolaanea AA, Al-Sindi TA. Lyophilized amorphous dispersion of telmisartan in a combined carrier–alkalizer system: formulation development and in vivo study. ACS Omega. 2020;5(50):32466-80. doi: 10.1021/acsomega.0c04588, PMID 33376884.

Giri BR, Kwon J, Vo AQ, Bhagurkar AM, Bandari S, Kim DW. Hot-melt extruded amorphous solid dispersion for solubility, stability, and bioavailability enhancement of telmisartan. Pharmaceuticals (Basel). 2021 Jan 18;14(1):73. doi: 10.3390/ph14010073, PMID 33477557, PMCID PMC7831136.

Patel B, Parikh RH, Swarnkar D. Enhancement of dissolution of Telmisartan through use of solid dispersion technique–surface solid dispersion. J Pharm Bioallied Sci. 2012 Mar;4Suppl 1:S64-8. doi: 10.4103/0975-7406.94142, PMID 23066211.